MABFORGE
Live / Applied — First extension granted (statement of use) (as of 10 Feb 2026)
What this means for you
Not registered yet, but its 03 May 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98532731
- Mark type
- Stylized text
- Filed
- 03 May 2024
- Published for opposition
- 03 Jun 2025
- Attorney of record
- Ian J. Block
Goods and services
- Class 001 — Chemicals: Protein molecules for scientific, laboratory and medical research use; Diagnostic reagents for scientific or research use; Chemicals for use in biotherapeutics and therapeutics product development and manufacturing processes, namely, chemicals for use in biotechnological product development; Biochemicals, namely, polypeptide encoding nucleic acids for laboratory research use; Monoclonal antibodies, antibody-based constructs, multispecific antibodies, antibody fragments, single-domain antibodies, engineered antibody formats, and antibody derivatives for scientific and medical laboratory research use
- Class 042 — Scientific and technological services: Research, development and consultation services in the fields of biotechnology, immunology, monoclonal antibodies, antibody-based constructs, multispecific antibodies, antibody fragments, single-domain antibodies, engineered antibody formats, antibody derivatives, vaccines, medicine, biotherapeutics, and therapeutics, namely, scientific research and development in the field of protein therapeutics, and conducting scientific research and development in the field of monoclonal antibodies, antibody-based constructs, multispecific antibodies, antibody fragments, single-domain antibodies, engineered antibody formats, and antibody derivatives for others; Genetic engineering services utilizing a collection of genetic technologies for the rapid production of human antibodies, human antibody fragments, and other proteins comprising such antibodies and fragments, namely, conducting genetic engineering for scientific research purposes for others, conducting testing, inspection, research, and development of protein therapeutic preparations for others; Scientific and medical research for use in antibody sequence humanization and optimization via deep mutational scanning (DMS); Conducting scientific medical and genetic research for others
- Class 045 — Legal and security services: Licensing of intellectual property to others in the fields of protein therapeutics, monoclonal antibodies, antibody-based constructs, multispecific antibodies, antibody fragments, single-domain antibodies, engineered antibody formats, and antibody derivatives
Owner
- Alloy Therapeutics, Inc., Waltham, MA, US
- Alloy Therapeutics, Inc., Waltham, MA, US
Prosecution history
- 11 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Feb 2026 — TEAS STATEMENT OF USE RECEIVED
- 10 Feb 2026 — SOU EXTENSION 1 GRANTED
- 10 Feb 2026 — SOU EXTENSION 1 FILED
- 10 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 07 Oct 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 05 Sept 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 05 Sept 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 05 Sept 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 03 Jun 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 03 Jun 2025 — PUBLISHED FOR OPPOSITION
- 28 May 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 30 Apr 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 28 Apr 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 28 Apr 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE